Children and adolescents [SmPC]
Single dose study: After a single dose of 500 mg metformin hydrochloride, pediatric patients showed the same pharmacokinetic profile as healthy adults.
Multi-dose study: Data are limited to one study. After repeated doses of 500 mg metformin hydrochloride twice daily for 7 days, maximum plasma concentration (Cmax) and systemic uptake (AUC0-t) were reduced by approximately 33 and 40%, respectively, compared to adult diabetics receiving repeated doses of 500 mg twice daily for 14 days. However, since the dose must be individually adjusted depending on blood glucose control, this is of limited clinical relevance.
Controlled one-year clinical trials in a limited number of patients aged between 10 and 16 years showed a similar effect on blood glucose control as in adults.
No information is present at this moment.
No information is present at this moment.
| Type 2 diabetes mellitus |
|---|
|
Adjustment in renal impairment as specified:
Note: Do not increase further in the event of an increased risk of dehydration or other reason risking sudden deterioration of renal function.
Accumulation of metformin can occur in patients with renal impairment.
Lactic acidosis can occur in rare cases. The reported cases of lactate acidosis in patients treated with metformin were primarily identified in diabetes patients with significant renal failure, although other risk factors may also play a role.
The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here
The side effects reported in children aged 10-16 years are the same in both nature and severity as in adult patients.
The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here
No information available on specific contra indications in children.
The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here
Carefully monitor the effects on growth and puberty in children, as long-term data on their effects are lacking.
The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here
This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.